Funded Biotechnology Startups in Oxford
Oxford's biotechnology sector shows funded rounds spanning $440K (Fermtech, September 2024) to $168M (Vaccitech, March 2021) across the 23 companies in thi…
Oxford's biotechnology sector shows funded rounds spanning $440K (Fermtech, September 2024) to $168M (Vaccitech, March 2021) across the 23 companies in this dataset. Activity runs from mid-2020 through October 2025, with early 2021 producing three large closes in rapid succession: Vaccitech's $168M Series B, Evox Therapeutics' $97M Series C, and SpyBiotech's $33M Series A, all within a five-week period.
Series B is the most common named stage across the group, claimed by five companies: Vaccitech, OXCCU, Grey Wolf Therapeutics ($50M, May 2024), Pathios Therapeutics ($25M, April 2024), and OMass Technologies ($13M, May 2023). Seven rounds carry the Series Unknown label, reflecting inconsistent stage disclosure across Oxford biotech deals. The dataset also includes two private equity rounds — Mirada Medical ($18M, June 2022) and GENinCode ($700K, August 2021) — alongside two seed-stage closes and one undisclosed-amount round from Albus Health.
Most recent rounds
23 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Oxford biotech companies?
The three largest are Vaccitech's $168M Series B (March 2021), Pepgen's $113M venture round (August 2021), and Evox Therapeutics' $97M Series C (February 2021). All three closed within the same calendar year, making 2021 the standout period for large Oxford biotech financings in this dataset. Osler Diagnostics' $85M Series C (November 2022) is the largest raise outside that 2021 cluster.
Which funding stage appears most often in this segment?
Seven rounds carry the Series Unknown label, making it the single most common classification. Among named stages, Series B accounts for five companies — Vaccitech, OXCCU, Grey Wolf Therapeutics, Pathios Therapeutics, and OMass Technologies — more than any other single disclosed stage.
How recent is the latest round in this dataset?
OXCCU closed a $28M Series B on October 4, 2025, the most recent round shown. The next most recent is Fermtech's $440K Series Unknown from September 29, 2024, followed by SynaptixBio's $3M round in August 2024.
How wide is the range in deal size across these companies?
Disclosed amounts span from $440K (Fermtech, September 2024) to $168M (Vaccitech, March 2021), roughly a 380x difference. Three companies raised under $1M — Fermtech, Oxford Cannabinoid Technologies ($720K), and GENinCode ($700K) — while four raised $85M or more. One company, Albus Health, has an undisclosed round dated January 2024.
Are there any seed-stage or early-stage companies in this group?
Two companies carry explicit Seed labels: HydRegen ($3M, April 2023) and OxCan ($2M, September 2021). Several Series Unknown rounds — including Fermtech at $440K and SynaptixBio at $3M — fall in size ranges consistent with pre-Series A activity, though their stages are not confirmed.
What round types outside of standard venture stages appear here?
Two companies closed private equity rounds: Mirada Medical ($18M, June 2022) and GENinCode ($700K, August 2021). Pepgen is classified as Venture - Series Unknown for its $113M close in August 2021, and Base Genomics carries no stage label on its $9M round from June 2020.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.